Previous 10 | Next 10 |
2023-06-07 17:31:50 ET Gainers: 4D Molecular Therapeutics( FDMT ) +21% . Semtech Corporation ( SMTC ) +15% . Acorda Therapeutics ( ACOR ) +10% . scPharmaceuticals ( SCPH ) +7% . Kezar Life Sciences ( KZR ) +6% . Loser...
2023-06-07 10:50:34 ET scPharmaceuticals ( NASDAQ: SCPH ) lost ~9% in the morning hours Wednesday after issuing an update on the commercial rollout of its recently launched heart failure therapy Furoscix. Ahead of a presentation at a healthcare conference, scPharma ( SCPH ...
2023-05-20 00:15:35 ET Summary SCPH's Furoscix, despite just launching, defied street consensus with an impressive $2.1M revenue in 1Q23, indicating a promising ramp trajectory. Witnessing a substantial increase in Furoscix's prescriptions and robust demand, supported by a growing...
2023-05-17 02:56:26 ET Summary Key update: as we predicted, FDA approval for LUMRYZ, a unique once-at-bedtime narcolepsy treatment. Orphan Drug Exclusivity is granted until May 1, 2030, offering attractive patent protection. Launch expected in June 2023, with a fast sales ramp ant...
2023-05-10 22:03:06 ET scPharmaceuticals Inc. (SCPH) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants PJ Kelleher – LifeSci Advisors John Tucker – Chief Executive Officer Steve Parsons – Senior Vice President of C...
2023-05-10 16:20:35 ET scPharmaceuticals press release ( NASDAQ: SCPH ): Q1 GAAP EPS of -$0.28 beats by $0.08 . Revenue of $2.1M beats by $0.53M . For further details see: scPharmaceuticals GAAP EPS of -$0.28 beats by $0.08, revenue of $2.1M beats by $0.53M
Announced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments o f $116.1 million Company to host investor conference call an...
BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceu...
2023-03-28 08:52:13 ET Summary SCPH launched Furoscix in February 2023 with 100% coverage by Medicare Part D and Medicaid and a fixed co-pay of approximately $100 for 60% of the target population. The company has made significant progress in physician detailing, reaching about 40%...
2023-03-23 11:20:02 ET scPharmaceuticals ( NASDAQ: SCPH ) stock rose ~21% on Thursday after its Q4 results wherein the company provided updates on its approved heart drug Furoscix. Net loss in 2022 widened to -$36.8M, compared to -$28M in 2021. The company said the net ...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...